Cannabinoid-Conjugated Gold Nanoparticles for Precise Dosage Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering cannabinoids in pain and cancer therapy face challenges such as unreliable dosage, low bioavailability, and unpredictable absorption due to inhalation and oral delivery methods, and existing nanocarrier systems are limited by toxicity, complexity, and lack of control over particle size and shape.
Innovation Solution
Development of cannabinoid-conjugated gold nanoparticles with a specific size range (5-20 nm) coated with polymers like peptides and hyaluronic acid, providing a stable and biocompatible nanocarrier system for intravenous or localized administration, enabling controlled and precise delivery of high payloads of cannabinoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If inhalation delivery methods (smoking, vaporization) are used, then rapid delivery of cannabinoids is achieved, but dosage reliability and bioavailability control deteriorate (2-56% variability)
Solution Approach 1:
The patent changes the physical-chemical parameters of cannabinoid delivery by converting them into nanoparticle form with specific size ranges (20-200 nm), surface charge properties, and encapsulation efficiency. This standardization of parameters enables precise dosage control while maintaining rapid delivery through intravenous or intranasal administration routes.
Solution Approach 2:
The patent replaces the mechanical act of smoking/vaporization with a controlled nanoparticle delivery system administered intravenously or intranasally. This substitution eliminates the variability introduced by user technique (puff number, hold time, inhalation volume) and provides reliable, reproducible dosage delivery.
2Ease of operation
If oral delivery methods are used, then ease of administration is improved, but bioavailability and onset time deteriorate (6% bioavailability, 1-5 hours delay)
Solution Approach 1:
The patent changes the bioavailability parameter from 6% (oral) to significantly higher levels by using nanoparticle encapsulation that protects cannabinoids from first-pass metabolism and enhances intestinal absorption. The nanoparticle size parameter (20-200 nm) is optimized to facilitate cellular uptake and bypass metabolic degradation.
Solution Approach 2:
The patent introduces nanoparticle carriers as intermediaries between the oral route and systemic circulation. These carriers protect cannabinoids from degradation in the stomach and during first-pass liver metabolism, enabling higher bioavailability while maintaining the ease of oral or non-invasive administration.
3Object-affected harmful factors
If organic nanocarrier systems are used, then biocompatibility is improved, but structural stability and control over particle size/shape deteriorate
Solution Approach 1:
The patent uses composite material structures combining organic biocompatible polymers with inorganic gold cores. This composite approach provides the biocompatibility of organic materials while the rigid gold core offers structural stability, defined geometry, and precise control over particle size and shape that organic materials alone cannot achieve.
Solution Approach 2:
The patent changes the material composition parameter by incorporating gold cores into the nanocarrier structure. This modification provides superior control over particle size (20-200 nm) and shape parameters while maintaining biocompatibility through appropriate surface functionalization and polymer coating.
4Ease of manufacture
If conventional synthetic procedures are used, then ease of manufacture is maintained, but control over nanocarrier structure and purity deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-functionalizing the nanoparticle surfaces with specific ligands, polymers, or targeting moieties before drug loading. This pre-preparation step establishes precise structural parameters, surface properties, and size distribution early in the synthesis process, which then guides subsequent drug encapsulation and ensures consistent product quality.
Solution Approach 2:
The patent changes the synthesis approach by using controlled nanoparticle formation methods that allow precise adjustment of size (20-200 nm), shape, and surface charge parameters. These parameter controls are maintained throughout the manufacturing process, enabling both ease of manufacture and high structural precision.
5Quantity of substance
If high payloads of cannabinoids are delivered, then therapeutic efficacy is improved, but toxicity and side effects worsen
Solution Approach 1:
The patent applies local quality by functionalizing different regions of the nanoparticle with different properties: the core provides high drug loading capacity, the surface provides biocompatibility and targeting specificity, and targeted ligands provide selective accumulation at the disease site. This spatial differentiation allows high local concentration of cannabinoids at the target while maintaining low systemic toxicity.
Solution Approach 2:
The patent uses nanoparticle carriers as intermediaries to deliver high payloads of cannabinoids to the target site. The carrier protects the high concentration of drug from causing systemic toxicity, provides selective targeting to reduce off-target effects, and enables controlled release to maintain therapeutic levels while minimizing side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances bioavailability, reduces cannabinoid dosages, ensures consistent plasma levels, and provides a standardized, safe, and economical method for targeted therapy, overcoming limitations of existing delivery methods and nanocarrier systems.
Implementation Method 1
The gold nanoparticles accumulate at the tumor site, taking advantage of the enhanced permeability and retention effect
Implementation Method 2
The outer shell of the particle is loaded with cannabinoid drug and a supporting polymer like peptides, chitosan, dextran, hyaluronic acid, polyvinyl polyvinylpyrrolidone (PVP), or polyvinyl alcohol (PVA), which renders the particles hydrophilic
Data Source
AI summary
The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration.